Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
The Cooper Companies, Inc. reports developments for a global medical device business organized around CooperVision and CooperSurgical. CooperVision news centers on soft contact lenses, specialty lens designs, myopia management products such as MiSight® 1 day, MyDay® contact lenses, practitioner support, and sustainability initiatives tied to lens materials, packaging, manufacturing, and plastic footprint programs.
CooperCompanies news also covers quarterly financial results, conference participation, board appointments, and governance matters. CooperSurgical provides fertility and women’s healthcare products, while companywide updates describe operating performance, capital priorities, and corporate developments across its medical device portfolio.
CooperCompanies (Nasdaq: COO) reported fiscal Q2 2026 revenue of $1.082 billion, up 8% year over year and 5% organically. GAAP diluted EPS was $(0.40), reflecting a litigation-related charge tied to a December 2023 fertility media recall, while non-GAAP diluted EPS rose to $1.21, up 26%.
Non-GAAP operating margin improved to 27%. CooperVision revenue was $723.5 million and CooperSurgical revenue $358.0 million, both up 8%. Free cash flow reached $96.4 million. Fiscal 2026 guidance calls for revenue of $4.285–$4.321 billion and non-GAAP EPS of $4.58–$4.66.
CooperVision (Nasdaq: COO) appointed Muru Annamalai as President, Asia-Pacific, effective June 1, 2026. He brings over 20 years of global healthcare and pharmaceutical leadership across Asia-Pacific, Latin America and other markets.
His background includes senior roles at AbbVie, Abbott, and TCA Venture Group, supporting healthcare innovation and growth.
CooperCompanies (Nasdaq: COO) appointed Paul Keel as an independent director, effective July 1, 2026, and named him to the Audit Committee. Mr. Keel brings CEO experience in medical devices and global operations, including roles at Envista, Smiths Group, and 3M. He holds an MBA from Harvard and a BA in Economics.
CooperCompanies (Nasdaq: COO) will report Q2 2026 financial results on Thursday, June 4, 2026 at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss results and corporate developments.
Dial-in: 800-715-9871 (Conference ID: 6529381). A simultaneous audio webcast and replay will be available at www.investor.coopercos.com.
CooperVision (Nasdaq: COO) launched the MADE BETTER™ Promise on April 9, 2026, beginning with the MyDay® daily disposable contact lens family.
The program uses ISCC PLUS-certified bio-attributed plastic in MyDay® blisters, manufacturing efficiency gains (≈30% lower GHG per lens at Puerto Rico site vs 2021), >90% recycling rates at production sites, and a plastic neutrality partnership that offset ~12.4M kg of coastal plastic waste (≈659M bottles) as of Feb 2026.
CooperCompanies (Nasdaq: COO) reported Q1 FY2026 revenue of $1.024 billion, up 6% year-over-year (3% organic). GAAP diluted EPS was $0.66 (+27%) and non-GAAP diluted EPS was $1.10 (+20%).
The company raised fiscal 2026 guidance to $4.306–$4.346 billion revenue, non-GAAP EPS $4.58–$4.66, and free cash flow $600–$625 million. Q1 free cash flow was $158.7 million and share repurchases totaled $92.5 million, with $873.9 million remaining on the program.
CooperVision (Nasdaq: COO) launched MiSight 1 day in Japan on Feb 10, 2026, marking the first soft contact lens authorized by Japan's Ministry of Health, Labor and Welfare for children to correct myopia and slow progression.
The lens is approved in >40 countries, features ActivControl technology, and showed an average 59% reduction in myopia progression after three years. Japan represents ~12% of the global contact lens market and faces an estimated 77% myopia rate among elementary school children.
CooperCompanies (Nasdaq: COO) will report first quarter 2026 financial results on Thursday, March 5, 2026 at 4:15 PM ET. A conference call will follow at 5:00 PM ET with dial-in 800-715-9871 (conference ID 6529381). A live audio webcast and replay are available at the company investor website.
CooperCompanies (Nasdaq: COO) will present at the J.P. Morgan Healthcare Conference on January 14, 2026. Al White, President and CEO, is scheduled to speak in a session beginning at 5:15pm ET. A live and archived webcast will be available on CooperCompanies' investor website for those who cannot attend the session in person.
CooperCompanies (Nasdaq: COO) appointed Walter M Rosebrough, Jr. as an independent director effective Jan 3, 2026 and entered a Cooperation Agreement with Browning West on Dec 23, 2025.
The Board agreed to seriously consider Mr. Rosebrough for Board Chair by end of 2026, to appoint a new independent director with medical technology experience (with Browning West’s mutual agreement), and to accept Browning West’s customary standstill and voting commitments. The Cooperation Agreement will be filed as an exhibit to a Form 8-K with the SEC.